Hepatitis C Eradication with Direct-Acting Antivirals: A Paradigm Shift in the Treatment of Indolent B-Cell Lymphomas
Posted inHematology-Oncology Infectious Diseases news

Hepatitis C Eradication with Direct-Acting Antivirals: A Paradigm Shift in the Treatment of Indolent B-Cell Lymphomas

Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially replacing chemotherapy as a first-line intervention.
Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
Posted inHematology-Oncology news Oncology

Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial

The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surveillance alone, offering a scalable model for population-level symptom management.
Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
Posted inAI Hematology-Oncology news Oncology

Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome

This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy safety through continuous monitoring and predictive modeling.
Posted inHematology-Oncology news Oncology

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep responses with initial ibrutinib-venetoclax, while sparing early responders from additional toxicity.
Posted inAllergy & Immunology Hematology-Oncology news

Precision Gene Correction via Prime Editing Restores NADPH Oxidase Activity in Patients with p47phox-Deficient Chronic Granulomatous Disease

A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target risks associated with traditional CRISPR-Cas9.
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Posted inHematology-Oncology news Oncology

Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia

Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patients with relapsed T-cell acute lymphoblastic leukemia.
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
Posted inHematology-Oncology Internal Medicine news

Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia

The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thrombocytopenia (ITP) compared to eltrombopag alone.
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
Posted inHematology-Oncology news Oncology

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high rates of complete response and minimal residual disease negativity.
Validated PRESEV Score Identifies Adults with Sickle Cell VOC at Low Risk for Acute Chest Syndrome — Implications for Safer Outpatient Management
Posted inHematology-Oncology news

Validated PRESEV Score Identifies Adults with Sickle Cell VOC at Low Risk for Acute Chest Syndrome — Implications for Safer Outpatient Management

An international prospective validation confirms the PRESEV score reliably identifies adult sickle cell patients hospitalized for vaso-occlusive crisis (VOC) who are at low risk for acute chest syndrome (ACS), enabling safer outpatient management strategies in selected patients.